Mydrane

Lidocaine Hydrochloride, Phenylephrine Hydrochloride, Tropicamide, the active ingredient in Mydrane, is a local anesthetic; alpha‑1 adrenergic agonist; antimuscarinic presented as an intracameral solution for intracameral use. It provides rapid pupil dilation and intraocular anesthesia during cataract and other ophthalmic surgeries.

GNH USA supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mydrane is employed in ophthalmic procedures to achieve mydriasis and intraocular anesthesia. - Cataract surgery: provides pupil dilation and intraocular anesthesia for safe lens removal. - Intraocular lens implantation: facilitates adequate mydriasis and analgesia during lens placement. - Other ophthalmic surgeries (e.g., trabeculectomy): enables sufficient pupil dilation and local anesthesia for surgical access.

Mydrane may cause ocular and systemic reactions following intracameral administration.

Common Side Effects: - Transient ocular irritation or burning sensation. - Temporary increase in intraocular pressure. - Mild corneal edema. - Brief blurred vision after injection. - Conjunctival hyperemia. - Mild headache.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Marked intraocular pressure spikes. - Persistent mydriasis lasting beyond the postoperative period. - Corneal ulceration or keratitis. - Endophthalmitis. - Retinal detachment.

Prior to Mydrane use, clinicians should assess ocular health and systemic conditions. - Patient assessment: evaluate for existing glaucoma or ocular hypertension. - Contraindications: known hypersensitivity to lidocaine, phenylephrine, tropicamide, or excipients. - Caution in glaucoma: monitor intraocular pressure closely. - Pediatric use: limited safety data; use only if benefits outweigh risks. - Drug interactions: review concurrent mydriatic or vasoconstrictive agents. - Store at controlled room temperature: keep in original container, protect from light and moisture, do not freeze.

Mydrane may interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Concurrent use of additional mydriatic agents may cause excessive pupil dilation. - Systemic phenylephrine with monoamine oxidase inhibitors can precipitate hypertensive crisis. - Co‑administration with other local anesthetics may increase neurotoxicity risk. - Use with potent vasoconstrictors may elevate systemic blood pressure.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs can enhance tropicamide‑induced dilation. - Prostaglandin analogs for glaucoma may affect intraocular pressure dynamics. - Beta‑blocker eye drops may alter cardiovascular response to phenylephrine. - Systemic antihypertensives may blunt phenylephrine’s effect, requiring dose adjustment.